AMW signs license and supply agreements for the commercialization of its goserelin and leuprorelin implants in Israel

-AMW grants your license to an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in Israel
-Increasing the availability of goserelin and leuprorelin for patients suffering from prostate cancer and breast cancer, as well as for other indications according to the approved marketing authorization.
-Expansion of AMW products in the MENA region

Warngau, October 19, 2021

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announced that it has entered into license and supply agreements (LSA) with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in the country of Israel.

AMW’s new partner is highly experienced in the registration and commercialization of pharmaceutical products and will help to bring improved medication to patients within Israel.

Under the terms of the agreements, the partner will distribute goserelin and leuprorelin in Israel. AMW will exclusively manufacture and supply goserelin and leuprorelin under pre-agreed terms and will receive royalty payments on its partner’s net sales.

To date, AMW has licensed goserelin and leuprorelin to global and local pharma leaders in more than 50 countries.

Konstantin Petropoulos, CEO of AMW GmbH, commented, “We are pleased to continue on our path of providing patients with prostate or breast cancer a wider reach for our products. As the market leader in biodegradable slow-release systems, we continue to make goserelin and leuprorelin available to patients around the world.”

For more information, please contact:
licensing@a-m-w.eu or
Dr. Konstantin Petropoulos
+49 8024 470999-0

About AMW:
AMW GmbH is a pharmaceutical company specializing in innovative drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or patches (transdermal). The company was founded in 2008 and develops therapeutic solutions in oncology, neurology, dermatology, pain management, and ophthalmology. AMW currently has four products on the market (implants for goserelin and leuprorelin, patches for rivastigmine and buprenorphine).
AMW is based in Warngau, south of Munich, Germany.

About Goserelin:
Goserelin belongs to the class of GnRH agonists (analogues of gonadotropin-releasing hormone), which intervene in the regulation of sex hormone balance. This has the effect of lowering testosterone levels in men and estradiol levels in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormone-sensitive tumors such as prostate cancer or breast cancer. In addition, goserelin is used to treat certain benign gynecological disorders. Goserelin is administered in the form of a biodegradable implant that releases the active ingredient over a period of one or three months.

About Leuprorelin:
Leuprorelin belongs to the class of GnRH agonists (analogues of gonadotropin-releasing hormone), which intervene in the regulation of sex hormone balance. This has the effect of lowering testosterone levels in men and estradiol levels in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormone-sensitive tumors such as prostate cancer or breast cancer. In addition, leuprorelin is used to treat certain benign gynecological conditions. Leuprorelin is administered in the form of a biodegradable implant that releases the active ingredient over a period of three months.